Journal
NATURE GENETICS
Volume 53, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41588-020-00749-z
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [T32 DK007780, F30 HG010822]
- NIH [F30 CA236129, T32 GM007170, T32 HG000046, U01 CA227550, 4DN U01 HL129998]
- NIH
- National Institute of Neurological Disorders [F30NS100595]
- E.V. McCollum Chair
- Bloomberg Distinguished Professorship
- Linda Pechenik Montague Investigator Award
- Cold Spring Harbor Laboratory
- NIH/National Cancer Institute Physical Science-Oncology Centers award [U54 CA193417]
- National Science Foundation CAREER award [1350601]
- SPORE [P50 CA174523]
- NIH Center for Photogenomics [RM1 HG007743]
- Tara Miller Foundation
- [DP5 OD028144]
- [R01CA207935]
- [P01 CA114046]
- [CA227550]
- [CA232256]
- [P30CA010815]
- [P30CA006973]
- [R01 CA238237]
- [P30 CA016520]
- Direct For Biological Sciences
- Div Of Molecular and Cellular Bioscience [1350601] Funding Source: National Science Foundation
Ask authors/readers for more resources
A genetic screen identified a new mode of altering resistance to BRAF inhibition in melanoma by increasing cellular plasticity and pushing cells towards a more differentiated state. Modulating cellular plasticity may alter cell fate decisions and prove useful for treating drug resistance in other cancers.
A genetic screen designed to capture modulators of single-cell state variability identifies a new mode of altering resistance to BRAF inhibition in melanoma that pushes cells toward a more differentiated state. Modulating cellular plasticity may provide a new avenue to overcome drug resistance. Cellular plasticity describes the ability of cells to transition from one set of phenotypes to another. In melanoma, transient fluctuations in the molecular state of tumor cells mark the formation of rare cells primed to survive BRAF inhibition and reprogram into a stably drug-resistant fate. However, the biological processes governing cellular priming remain unknown. We used CRISPR-Cas9 genetic screens to identify genes that affect cell fate decisions by altering cellular plasticity. We found that many factors can independently affect cellular priming and fate decisions. We discovered a new plasticity-based mode of increasing resistance to BRAF inhibition that pushes cells towards a more differentiated state. Manipulating cellular plasticity through inhibition of DOT1L before the addition of the BRAF inhibitor resulted in more therapy resistance than concurrent administration. Our results indicate that modulating cellular plasticity can alter cell fate decisions and may prove useful for treating drug resistance in other cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available